Ready to improve your ICU knowledge? Check out ICU Trials for iPhone and Android, a pocket reference for 70+ landmark critical care trials, including ANZICS Dopamine.
Summary of the ANZICS Dopamine (Bellomo 2001) Trial
The use of “renal dose” dopamine did not reduce peak creatinine, the need for renal replacement therapy, ICU length of stay, or mortality.
Key Points from ANZICS Dopamine (Bellomo 2001)
- Included 328 patients with SIRS, a central line, and at least one indicator of early renal dysfunction (UOP < 0.5 mL/kg over 4 hrs, creatinine > 1.7 mg/dL, or a creatinine increase of > 0.9 mg/dL over 24 hrs)
- Randomized patients to receive dopamine 2 mcg/kg/min or placebo until renal replacement therapy, death, discharge from ICU, or renal dysfunction and SIRS resolved for > 24 hrs
- Most included patients had septic shock and were receiving mechanical ventilation
- Primary endpoint (peak serum creatinine during trial infusion) was not difference between dopamine and placebo groups
- Absolute increase in creatinine and the need for renal replacement therapy (21.7% vs. 24.5%) were not different between groups. Similarly, there was no difference in urine output at 1, 24, or 48 hours
- No difference in duration of mechanical ventilation, ICU/hospital length of stay, or mortality
Citation
Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet. 2000 Dec 23-30;356(9248):2139-43. PMID 11191541
